Anti-invasive effect of MMI-166, a new selective matrix metalloproteinase inhibitor, in cervical carcinoma cell lines

Gynecologic Oncology

Volumn 85, Issue 1, 2002, Pages 103-107

  Iwasaki, Masahiro ^a   Nishikawa, Akira ^a   Fujimoto, Takashi ^a   Akutagawa, Noriyuki ^a   Manase, Kengo ^a   Endo, Toshiaki ^a   Yoshida, Koichi ^a   Maekawa, Ryuji ^b   Yoshioka, Takayuki ^b   Kudo, Ryuichi ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SHIONOGI AND CO LTD   (Japan)

Author keywords

Cervical carcinoma; Invasion; MMP inhibitor

Indexed keywords

GELATINASE A; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE INHIBITOR; MMI 166; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CONTROLLED STUDY; CYTOTOXICITY; ENZYME INHIBITION; FEMALE; GYNECOLOGIC CANCER; HUMAN; HUMAN CELL; PRIORITY JOURNAL; UTERINE CERVIX CARCINOMA;

EID: 0036229113     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2001.6573     Document Type: Article

References (37)

1. Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation
2. Tumor cell interactions with the extracellular matrix during invasion and metastasis
3. Metastatic potential correlates with enzymatic degradation of basement membrane collagen
4. Urokinase and urokinase receptor: A paracrine/autocrine system regulating cell migration and invasiveness
5. Activation mechanisms of matrix metalloproteinases
6. H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen
7. SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages
8. Characterization of extracellular matrix-degrading proteinase and its inhibitor in gynecologic cancer tissues with clinically different metastatic form
9. Expression of matrix metalloproteinase-9 in squamous cell carcinoma of the uterine cervix-clinicopathologic study using immunohistochemistry and mRNA in situ hybridization
10. Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma
11. In situ detection of PCR-amplified metalloproteinase cDNAs, their inhibitors and human papillomavirus transcripts in cervical carcinoma cell lines
12. A matrix metalloproteinase expressed on the surface of invasive tumour cells
13. Isolation of a mouse MT2-MMP gene from a lung cDNA library and identification of its product
14. Identification of the second membrane-type matrix metalloproteinase (MT-MMP-2) gene from a human placenta cDNA library. MT-MMPs form a unique membrane-type subclass in the MMP family
15. MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma - A clinicopathologic study using immunohistochemistry and mRNA in situ hybridization
16. High level of MT-MMP expression is associated with invasiveness of cervical cancer cells
17. AAC-11 overexpression induces invasion and protects cervical cancer cells from apoptosis
18. Matrix metalloproteinase inhibitors: A new class of anticancer agent
19. Recent advances in matrix metalloproteinase inhibitor research
20. Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer
21. Matrix metalloproteinase inhibitors: Present achievements and future prospects
22. Emerging therapeutic advances for the development of second generation matrix metalloproteinase inhibitors
23. Matrix metalloproteinase inhibitors as a novel anticancer strategy: A review with special focus on Batimastat and Marimastat
24. Recent advances in inhibitors of matrix metalloproteinases for cancer therapy
25. Clinical potential of matrix metalloproteinase inhibitors
26. Anti-metastatic efficacy and safety of MMI-166, a selective matrix metalloproteinase inhibitor
27. Established and characterization of a cell line derived from human uterine cervical adenocarcinoma and its chemosensitivity to antitumor drugs
28. Studies on a new human cell line (SiHa) derived from carcinoma of uterus. I. Its establishment and morphology
29. Tumor antigen and human chorionic gonadotropin in CaSki cells: A new epidermoid cervical cell lines
30. Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives
31. Correlation of antiangiogenic and antitumor efficacy of N-biphenyl sulfonyl-phenylalanine hydroxiamic acid (BPHA), an orally-active, selective matrix metalloproteinase inhibitor
32. Expression of various matrix proteases and Ets family transcriptional factors in ovarian cancer cell lines: Correlation to invasive potential
33. Isolation and characterization of rat and human glyceraldehyde-3-phosphate dehydrogenase cDNAs: Genomic complexity and molecular evolution of the gene
34. Coordinate induction and activation of metalloproteinase and ascorbate depletion in structural luteolysis
35. Activation of the precursor of gelatinase A/72 kDa type IV collagenase/MMP-2 in lung carcinomas correlates with the expression of membrane-type matrix metalloproteinase (MT-MMP) and with lymph node metastasis
36. Dupuytren's disease and frozen shoulder induced by treatment with a matrix metalloproteinase inhibitor
37. Antitumor effect of a new selective matrix metalloproteinase inhibitor, MMI-166, on experimental pancreatic cancer